

OSCIENT PHARMACEUTICALS CORP  
 Form 4  
 August 17, 2005

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BB BIOVENTURES L P**

2. Issuer Name and Ticker or Trading Symbol  
**OSCIENT PHARMACEUTICALS CORP [OSCI]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
**C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVE., 31ST FLOOR**

3. Date of Earliest Transaction (Month/Day/Year)  
**08/15/2005**

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  Other (specify below)  
**Former 10% owner**

(Street)  
**BOSTON, MA 02199**

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)  
 \_\_\_\_ Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| Common Stock                    | 08/15/2005                           |  | S                              | (A)<br>50,000<br>(1) D  | \$ 2.607 7,482,050  | I  | See footnote (2)                                      |
| Common Stock                    | 08/16/2005                           |  | S                              | (A)<br>150,000<br>(3) D   | \$ 2.6424 7,332,050   | I  | See footnote (4)                                      |
| Common Stock                    | 08/17/2005                           |  | S                              | (A)<br>160,000<br>(5) D   | \$ 2.6615 7,172,050   | I  | See footnote (6)                                      |

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Transaction (Instr. 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares  |

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

|   |                  |
|---|------------------|
| BB BIOVENTURES L P<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVE., 31ST FLOOR<br>BOSTON, MA 02199                         | Former 10% owner |
| MPM BIO VENTURES PARALLEL FUND L P<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVE., 31ST FLOOR<br>BOSTON, MA 02199         | Former 10% owner |
| MPM ASSET MANAGEMENT INVESTORS 1998 LLC/MA<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVE., 31ST FLOOR<br>BOSTON, MA 02199 | Former 10% owner |
| BAB BIO VENTURES LLP<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVE., 31ST FLOOR<br>BOSTON, MA 02199                       | Former 10% owner |
| BAB BIO VENTURES NV<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVE., 31ST FLOOR  | Former 10% owner |

BOSTON, MA 02199

MPM BIO VENTURES I LP  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVE., 31ST FLOOR  
BOSTON, MA 02199

Former 10% owner

MPM BIO VENTURES I LLC  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVE., 31ST FLOOR  
BOSTON, MA 02199

Former 10% owner

GADICKE ANSBERT  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVE., 31ST FLOOR  
BOSTON, MA 02199

Former 10% owner

STEINMETZ MICHAEL  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVE., 31ST FLOOR  
BOSTON, MA 02199

Former 10% owner

EVNIN LUKE  
C/O MPM ASSET MANAGEMENT  
111 HUNTINGTON AVE., 31ST FLOOR  
BOSTON, MA 02199

X

Former 10% owner

## Signatures

By Luke Evnin, manager of BAB BioVentures, N.V., the general partner of BB BioVentures L.P. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

By Luke Evnin, manager of MPM BioVentures I L.P. and MPM BioVentures I LLC, the general partners of BB BioVentures Parallel Fund, L.P. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

By Luke Evnin, manager of MPM Asset Management Investors 1998 LLC. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

By Luke Evnin, manager of BAB BioVentures, N.V., the general partner of BAB BioVentures L.P. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

By Luke Evnin, manager of BAB BioVentures, N.V. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

By Luke Evnin, manager of MPM BioVentures I LLC. /s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

/s/ Michael Steinmetz

08/17/2005

\_\_Signature of Reporting Person

Date

/s/ Ansbert Gadicke

08/17/2005

\_\_Signature of Reporting Person

Date

/s/ Luke Evnin

08/17/2005

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares were sold as follows: 43,800 by BB BioVentures L.P. ("BB BV"), 5,626 by MPM BioVentures Parallel Fund, L.P. ("BV PF") and 575 by MPM Asset Management Investors 1998 LLC ("AM 1998"). MPM BioVentures I, L.P. ("BV I") and MPM BioVentures I

- (1) LLC ("BV I LLC") are the direct and indirect general partners of BV PF. BAB BioVentures L.P. ("BAB BV") and BAB BioVentures, N.V. ("BAB NV") are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadicke and Michael Steinmetz are the managers of BAB NV, AM 1998 and BV I LLC.
- (2) The shares are held as follows: 6,052,862 by BB BV, 777,393 by BV PF and 79,459 by AM 1998. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (3) The shares were sold as follows: 131,399 by BB BV, 16,876 by BV PF and 1,725 by AM 1998.
- (4) The shares are held as follows: 6,421,758 by BB BV, 825,976 by BV PF and 84,316 by AM 1998. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (5) The shares were sold as follows: 140,136 by BB BV, 18,024 by BV PF and 1,840 by AM 1998.
- (6) The shares are held as follows: 6,281,622 by BB BV, 807,952 by BV PF and 82,476 by AM 1998. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.